ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue54,51552,22245,658
Cost of Revenue27,46628,81719,458
Gross Profit27,04923,40526,200
Operating Expenses
Research Development13,14721,12719,731
Selling General and Administrative30,35326,39526,931
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-16,451-24,117-20,462
Income from Continuing Operations
Total Other Income/Expenses Net1,131-122-22
Earnings Before Interest and Taxes-15,320-24,239-20,484
Interest Expense1,4231,4231,423
Income Before Tax-16,743-24,239-20,484
Income Tax Expense-100175
Minority Interest---
Net Income From Continuing Ops-16,743-24,339-20,659
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-16,743-24,339-20,659
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-16,743-24,339-20,659